{
  "Cancer Histology Subtype (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3872, 
        3880
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4022, 
        4032
      ]
    }
  ], 
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3681, 
        3690
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3788, 
        3797
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3852, 
        3861
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3409, 
        3432
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        8645, 
        8665
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3567, 
        3594
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3620, 
        3624
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3716, 
        3720
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3802, 
        3806
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4169, 
        4173
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4295, 
        4299
      ]
    }, 
    {
      "__agreement__": "FALSE POSITIVE", 
      "__annotator__": "Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        8519, 
        8523
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        8541, 
        8545
      ]
    }
  ], 
  "Lymphatic System Location (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3599, 
        3618
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3656, 
        3666
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3763, 
        3773
      ]
    }, 
    {
      "__agreement__": "FALSE POSITIVE", 
      "__annotator__": "Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        8524, 
        8537
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        8546, 
        8559
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        797, 
        826
      ]
    }
  ], 
  "Microscopic Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        8411, 
        8446
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        8488, 
        8514
      ]
    }
  ], 
  "Negative Findings Phraseology (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3668, 
        3690
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3775, 
        3797
      ]
    }, 
    {
      "__agreement__": "FALSE NEGATIVE", 
      "__annotator__": "Gemma", 
      "__extent": [
        4378, 
        4420
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3649, 
        3655
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3756, 
        3762
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4222, 
        4228
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4346, 
        4352
      ]
    }
  ], 
  "Neoplasm Descriptive Grade (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3887, 
        3922
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3807, 
        3813
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4174, 
        4180
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4229, 
        4242
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4300, 
        4306
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3596, 
        3598
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3692, 
        3694
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3799, 
        3801
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4166, 
        4168
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4292, 
        4294
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        8516, 
        8517
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        8538, 
        8539
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        8570, 
        8571
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        8589, 
        8590
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        8617, 
        8618
      ]
    }
  ], 
  "Synoptic Report Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4422, 
        4439
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PathSys|Associated Pathologists, LLC d/b/a PathGroup^44D0658987^CLIA|eMARCPlus|TN Cancer Registry|20170919125833||ORU^R01^ORU_R01|201709191258330001|P|2.5.1|TN||||||||VOL_V_40_ORU_R01-CCR1^NAACCR_CP\nOBR|1||17-51-003175^PathSys^44D0658987^CLIA|11529-5^SURGICAL PATH REPORT^LN|||20170808000000|||||||20170808000000|&Sentinel Lymph Node, Sentinel Lymph Node, Breast, Exc. of Lesion, requiring micro. margins, Breast, Exc. of Lesion, requiring micro. margins, Breast, Exc. of Lesion, requiring micro. margins, PQRS Br|1538157219^^^^^^MD^^CMS^D^^^NPI||||||20170809000000|||F||||||C50.512^Malignant neoplasm of lower-outer quadrant of left female breast^I10~D05.12^Intraductal carcinoma in situ of left breast^I10~Z17.0^Estrogen receptor positive status [ER+]^I10|1942526447&&&S&&&&&CMS\n\n\n\n\n\n\n\nPath report.gross description\n\n1. , left sentinel node #1. Received fresh is a portion of yellow, lobulated, adipose tissue that measures 1.5 x 1.0 x 0.6 cm. The specimen is bisected to reveal probable tan lymph node tissue. The node is entirely submitted for frozen section diagnosis. 2. Received designated \"specimen 2 left axillary node palpable (count 19) fresh\" is a single yellow-tan, lobulated portion of fatty tissue with a small palpable lymph node. Sectioning reveals what appears to be a largely fatty replaced lymph node which is 8 mm in greatest dimension. No obvious gross metastases are present. Lymph node material is entirely submitted for frozen section diagnosis. 2FSC 2/1. (WJL/blc) 3. Received fresh designated \"left breast lumpectomy\" is a lumpectomy specimen with multiple orienting sutures. The specimen is 40 x 21 x 16 mm. Small palpable firm nodule is present in the specimen. Long suture denotes lateral, short suture denotes superior, uneven suture denotes deep, single is superficial. The deep margin is marked with silver nitrate. Lateral margin is marked with blue ink, medial margin is denoted with black ink, superior is denoted with green ink and superficial is left uninked. The specimen is serially sectioned from superficial to deep revealing an 11 mm gelatinous focus which extends to within approximately 2 mm of the deep margin, remaining margins are grossly negative. Multiple representative sections are submitted following additional fixation. Summary of sections: 3A-3D, 1/4 4. Received in formalin labeled \"\" and \"medial-additional margin (requisition further indicates stitch on new medial side)\" is an irregular portion of fatty yellow tissue measuring 2.7 x 2.0 x 1.0 cm containing a suture (per requisition this is a new medial side). The new medial margin is inked blue. The opposing surface is left uninked. Sectioning perpendicular to the long axis reveals a lobulated pale yellow cut surface. No firm areas, masses or lesions are grossly identified. The specimen is entirely submitted in cassettes 4A and 4B, 4A, 3/1; 4B, 2/1. (SB20/eh) 5. Received in formalin labeled \"\" and \"deep additional margin (requisition further indicates stitch on new deep side)\" is an irregular portion of fatty tissue containing a suture measuring 2.3 x 1.3 x 1.2 cm (the suture per requisition indicates the new deep side). The new deep margin is inked blue. the opposing side is left uninked. Sectioning reveals a lobulated fatty cut surface. No firm areas or masses are grossly identified. The specimen is entirely submitted in cassettes 5A and 5B, 5A 3/1, 5B 2/1. (SB20/eh)\n\n\nPath report.relevant Hx\n\nHistory - Left breast cancer, invasive, C50.919 Malignant neoplasm of unsp site of unspecified female breast, Left musonous cancer\n\n\nPath report.final diagnosis\n\n1. Sentinel lymph node, left axilla, biopsy:     One benign lymph node, negative for carcinoma. 2. Palpable lymph node, left axilla (count 19), biopsy:     One benign lymph node, negative for carcinoma. 3. Left breast, lumpectomy:     Infiltrating mammary carcinoma (1.1 cm), mucinous type, low combined       histologic grade with low proliferation rate.     Associated ductal carcinoma in situ (DCIS), nuclear grade 2 of 3, cribriform       type.     All final margins are widely negative for invasive and in situ carcinoma.     No lymphovascular invasion identified. 4. Left breast, additional medial margin, excision:     Benign breast tissue.     Negative for invasive or in situ carcinoma. 5. Left breast, additional deep margin, excision:     Benign fibroadipose tissue.     Negative for invasive or in situ carcinoma. CANCER CHECKLIST: INVASIVE CARCINOMA OF THE BREAST: Complete Excision (Less Than Total Mastectomy, Including Specimens Designated Biopsy, Lumpectomy, Quadrantectomy, and Partial Mastectomy With or Without Axillary Contents) and Mastectomy (Total, Modified Radical, Radical With or Without Axillary Contents)Radical, Radical With or Without Axillary Contents) 2.006.001.1000043  Clinical History: Palpable mass  Radiologic Finding: Mass or architectural distortion  Procedure: Excision with image-guided localization  Lymph Node Sampling: Sentinel lymph node(s)  Specimen Laterality: Left  Primary Tumor Site: Invasive Carcinoma: Lower outer quadrant  Specify Clock Position of Tumor Site: 3 o'clock, 4 o'clock  Histologic Type: Mucinous carcinoma  Glandular (Acinar) / Tubular Differentiation: Score 2 (10 to 75% of tumor area forming glandular / tubular structures)  Nuclear Pleomorphism: Score 2 (Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and shape)  Mitotic Rate: Score 1 (<=3 mitoses per mm2)  Number of Mitoses per 10 High-Power Fields: 1mitotic figures  Diameter of Microscope Field (mm): 0.55mm  Overall Grade: Grade 1 (scores of 3, 4 or 5)  Ductal Carcinoma In Situ (DCIS): DCIS is present, Negative for extensive intraductal component (EIC)  Architectural Patterns: Cribriform  Nuclear Grade (see Table 2 in CAP Protocol): Grade II (intermediate)  Necrosis: Not identified  Lobular Carcinoma In Situ (LCIS): Not identified  Greatest Dimension (mm): 11mm  Additional Dimension (mm): 8mm, 6mm  Tumor Focality: Single focus of invasive carcinoma  Skin: Skin is not present  Skeletal Muscle: No skeletal muscle is present  Lymph-Vascular Invasion: Not identified  Dermal Lymph-Vascular Invasion: No skin present  Microcalcifications: Not identified  Treatment Effect: Response to Presurgical (Neoadjuvant) Therapy: No known presurgical therapy  Invasive Carcinoma: Margins uninvolved by invasive carcinoma  Anterior: greater than 10mm  Posterior: greater than 10mm  Superior: greater than 10mm  Inferior: greater than 10mm  Medial: greater than 10mm  Lateral: 10mm  Distance from Closest Margin: Distance (specify in mm)  Distance (specify in mm): 10mm  Closest Uninvolved Margin: Lateral  Ductal Carcinoma In Situ (DCIS): Margins uninvolved by DCIS (DCIS present in specimen)  Anterior: greater than 10mm  Posterior: greater than 10mm  Superior: greater than 10mm  Inferior: greater than 10mm  Medial: greater than 10mm  Lateral: greater than 10mm  Distance of DCIS from Closest Margin (mm): Distance is > 10 mm  Closest Uninvolved Margin(s): Lateral  Sentinel Node Status: Sentinel lymph node biopsy performed  Number of Sentinel Nodes Examined: Specify number  Specify number: 1  Method of Evaluation of Sentinel Lymph Node(s): Hematoxylin and eosin (H and E), one level  Number of Lymph Node(s) Examined (sentinel and nonsentinel): Specify number  Specify number: 2  Lymph Node Involvement: None identified  Primary Tumor (Invasive Carcinoma) (pT): pT1c: Tumor > 10 mm but <= 20 mm in greatest dimension  Modifier: (sn): Only sentinel node(s) evaluated. If 6 or more nodes (sentinel or nonsentinel) are removed, this modifier should not be used.  Category (pN): pN0: No regional lymph node metastasis identified histologically  Distant Metastasis (pM): Not applicable - pM cannot be determined from the submitted specimen(s) BREAST: Biomarker Reporting Template 1.001.001.1000043 TEST(S) PERFORMED on biopsy 17-51-2802  Test(s) Performed: Estrogen Receptor (ER) Status, Progesterone Receptor (PgR) Status, HER2 by Immunohistochemistry (IHC), HER2 (ERBB2) by In Situ Hybridization (ISH)  ER Results: Positive  Percentage of Cells with Nuclear Positivity#: Specify %  Average Intensity of Staining: Strong  PgR Results: Positive  Percentage of Cells with Nuclear Positivity#: 91-100%  Average Intensity of Staining: Strong  HER2 IHC Results: Negative (Score 0)  HER2 (ERBB2) ISH Results: Negative (not amplified)\n\n\nPath report.microscopic examination\n\nMicroscopic examination is performed.\n\n\nPath report.site of origin\n\n1. Left sentinel node 2. Left axillary node, palpable 3. Left lumpectomy 4. Medial additional margin 5. Deep additional margin\n\n\nPath report.comments\n\nComments - The separate studies were previously performed on biopsy 17-51-2802. The neoplastic cells were positive for nuclear estrogen receptor and positive for nuclear progesterone receptor. Neoplastic cells were negative for Her2 amplification by immunohistochemistry and FISH.\n\n\n"
}